Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
THE WOODLANDS, Texas, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed the ruling of the United States District Court for the Southern District of Texas in favor of the Company in the Company’s motions for summary judgment that Dr. Fisch failed to present sufficient evidence to be added as a co-inventor of U.S. Patent Nos. 7,737,185 and 7,759,360, covering therapeutic uses of enclomiphene, and that equitable estoppel barred Dr. Fisch's counterclaims seeking to be added as a co-inventor of the patents at issue, in its lawsuit against Dr. Harry Fisch.
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
For more information, please visit the Company’s website at http://www.reprosrx.com.
CONTACT: Investor Relations: Thomas Hoffmann The Trout Group (646) 378-2931 [email protected]
